Double Helix Biotechnology Dev. has been acquired by Interpublic Group of Companies
June 2012 — Double Helix Bio-Technology Development Ltd. (Double Helix), a leading, global provider of market research and market access services to the pharmaceutical and medical device industries, has been sold to McCann Health, owned by The Interpublic Group of Companies Inc. Financial details of this transaction have not been disclosed.
Founded by Dr Wayne Phillips and based in London, Double Helix not only specializes in the established markets of the US and Europe, but also focuses on emerging markets, providing clients with a truly global perspective. In the past year, Double Helix has performed projects across more than 40 countries for over 30 major pharmaceutical multinational clients. Dr Phillips will continue as CEO of Double Helix, reporting to John Cahill, CEO of McCann Health.
McCann Health is a part of McCann Worldgroup, the largest marketing communications agency network in the world, and is a leading healthcare agency network owned by The Interpublic Group of Companies Inc.
Our role in the transaction
Oaklins Cavendish, based in the UK, acted as financial advisor to the seller.
Talk to the deal team
Lord Leigh of Hurley
Oaklins Cavendish
Related deals
Comtax has been acquired by Ryan
Comtax, a São Paulo-based tax technology consultancy specializing in tax determination and digital tax compliance, had been acquired by Ryan, the world’s largest firm dedicated exclusively to business taxes. The transaction marks Ryan’s entry into the Brazilian market, adding a specialized team and an established base of large corporate clients in Brazil, one of the world’s most complex tax environments, at a time when the country’s consumption tax reform is set to reshape how companies calculate and report indirect taxes. For Comtax, the acquisition brings access to Ryan’s global platform, technology and client network across more than 80 countries, creating opportunities to scale its tax determination and compliance offering beyond its current footprint. Comtax’s founders will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreNextalia has acquired a majority stake in Witapp
Nextalia SGR S.p.A. has acquired a majority stake in Witapp S.r.l., an Italian company specializing in software development for the digitization of healthcare infrastructure. The acquisition strengthens Nextalia’s track record in technology companies serving the public sector and supports its strategy of investing in businesses operating at the intersection of healthcare digitization and the modernization of public services.
Learn more